| LncRNA |
Compound |
Cancer |
P-value |
Effect |
| ENSG00000265688.1 |
ABT-263 (navitoclax) |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
0.033293856 |
Resistant |
| ENSG00000265688.1 |
ABT-263 (navitoclax) |
Lymphoid neoplasm diffuse large B-cell lymphoma |
0.038864892 |
Resistant |
| ENSG00000265688.1 |
ABT-263 (navitoclax) |
Pancreatic adenocarcinoma |
0.031092792 |
Sensitive |
